- Ritedose is investing over $17 million to expand its cGMP analytical chemistry and microbiology laboratories.
- The expansion will triple laboratory space and is scheduled for completion in spring 2026.
The Ritedose Corporation has announced a $17 million investment to expand its in-house cGMP laboratory facilities, enhancing both analytical chemistry and microbiology capabilities. The project will add 10,000 square feet of laboratory space and provide advanced analytical services to support its annual growth capacity of 2.6 billion doses.
The expansion will be completed in two phases. Phase I involves the creation of a new 10,000-square-foot analytical chemistry laboratory at the recently opened distribution and logistics facility within Ritedose Performance Park. Phase II will convert the company’s current analytical chemistry laboratory into a 6,000-square-foot expansion for microbiology services. Both phases are expected to be completed by spring 2026.
“By expanding our cGMP laboratory space, we’re not just meeting our current needs, we’re preparing Ritedose for the future of pharmaceutical development.”
CEO Jody Chastain
The expanded facilities will triple the company’s laboratory footprint, streamlining operations, supporting method development, validation, stability studies, and enabling comprehensive analytical testing. These include extractables and leachables, nitrosamine detection, elemental analysis and drug product de-formulation.
This investment follows recent growth initiatives by Ritedose, including a new logistics and distribution facility, additional packaging capacity, and an increase of 180 million sterile BFS units for ophthalmic and respiratory therapies.
